Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Not Yet Recruiting Phase 2 Trials for Methotrexate (DB00563)

IndicationStatusPhase
DBCOND0030602 (Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03602898Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationTreatment